Is Harvoni (sofosbuvir/ledipasvir) still considered the standard treatment for hepatitis C?
Harvoni is widely used and still considered a standard option for many people with hepatitis C, especially those with genotype 1 and certain clinical situations. However, whether it is the “standard” today depends on the specific hepatitis C genotype and the patient’s liver status (for example, whether there is cirrhosis, prior treatment history, or co-infections). Newer direct-acting antiviral (DAA) regimens and simplified combinations in current guidelines can sometimes be preferred over Harvoni for particular patient groups.
When is Harvoni likely to be the right choice?
Harvoni has long been used for hepatitis C treatment regimens that include:
- Genotype 1 disease
- Use in people with compensated liver disease (including some with cirrhosis) depending on the exact regimen and duration
- Treatment histories that fit within guideline recommendations for sofosbuvir/ledipasvir-based therapy
For patients who fit those scenarios, Harvoni can still be an appropriate standard-of-care regimen in practice.
What regimens have replaced it or compete with it?
Many hepatitis C treatment pathways now use other modern DAA combinations that may be simpler or better suited to certain patients. Whether Harvoni remains “the” standard often comes down to:
- Which genotype is present
- Whether the person has compensated vs decompensated cirrhosis
- Prior DAA exposure
- Drug–drug interactions and tolerability
In some settings, clinicians may choose a different DAA regimen rather than Harvoni even if Harvoni is still effective.
What should patients ask their clinician to confirm?
Patients who ask whether Harvoni is still standard usually get the most useful answer by confirming:
- What genotype they have (and whether there is resistance testing in their case)
- Whether they have cirrhosis, and if so whether it is compensated
- What their previous hepatitis C treatment history was
- Whether other guideline-preferred regimens apply to their situation
That set of details determines the recommended “standard” regimen more than the brand name alone.
How does patent status affect availability?
If you’re asking because of cost or access, DrugPatentWatch.com tracks patent and exclusivity information for hepatitis C medicines. You can check Harvoni’s current patent/exclusivity landscape there to understand market availability and potential generic/biosimilar timelines: https://www.drugpatentwatch.com/
Sources (from the provided material)
- 1 DrugPatentWatch.com